Breaks Categories: News

TuesdayMay 07, 2024 2:13 pm

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) and Bollinger Motors Partner with Amerit Fleet Solutions to Offer Warranty and Mobile Service

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, and its subsidiary, Bollinger Motors, have entered into an agreement with Amerit Fleet Solutions, a leading provider of customized fleet maintenance and repair programs nationwide. The agreement calls for Amerit to provide mobile service and maintenance to Bollinger’s commercial fleet customers. According to the announcement, Bollinger and Amerit will collaborate to provide EV service and warranty support for the Bollinger B4, as well as other vehicles developed by Bollinger. Specifically, Amerit will provide maintenance, repair and warranty services to Bollinger customers located outside of the designated service area of a Bollinger…

Continue Reading

TuesdayMay 07, 2024 2:12 pm

NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the…

Continue Reading

TuesdayMay 07, 2024 2:05 pm

NetworkNewsBreaks – GEMXX Corporation (GEMZ) Announces Expansion Efforts, Appoints New Board Member

GEMXX (OTC: GEMZ), a leading provider of exquisite gemstone jewelry, is expanding its business model to include private equity funding for oil and gas (“O&G”) exploration. According to the announcement, the company is leveraging already-established relationships around the world as well as newly formed strategic partnerships to create a new business channel designed to fund exploration of giant (500 million barrels) and super-giant (3 billion+ barrels) oil fields located in Latin America. This strategic decision allows the company to “tap into moderate-risk, high-reward onshore O&G opportunities,” the announcement noted. GEMXX will be focused on  overlooked and underexplored basins. As part…

Continue Reading

TuesdayMay 07, 2024 1:51 pm

NetworkNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), American West Metals Eye New Targets at Storm Copper Project

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF) today presented preliminary interpretation of the initial results from geophysical activities currently underway at the Storm Copper Project on Somerset Island, Nunavut. The program is being conducted by the operator of the project, American West Metals Limited. America West has completed the required expenditures to earn an undivided 80% interest in the project and will be solely responsible for funding the program. “It is very encouraging to see geophysics identify new targets at Storm,” said Thomas Ullrich, CEO of Aston Bay. “Moving Loop EM anomalies have demonstrated a very strong correlation with high-grade copper…

Continue Reading

TuesdayMay 07, 2024 1:16 pm

NetworkNewsBreaks – PaxMedica Inc. (PXMD) Continues Advancement of PAX-101 Regulatory Strategy

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has issued a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. “Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (‘ASD’),” said Howard Weisman, CEO of PaxMedica, further emphasizing the company’s efforts to advance healthcare solutions globally. “We are not…

Continue Reading

TuesdayMay 07, 2024 12:25 pm

NetworkNewsBreaks – Energy and Water Development Corp. (EAWD) CEO Featured in Most Recent Episode of The Bell2Bell Podcast

Energy and Water Development (OTCQB: EAWD), a green-tech engineering solutions company focused on delivering water and energy to extreme environments, is spotlighted in the latest episode The Bell2Bell Podcast, released by IBN. A multifaceted communications organization focused on connecting public companies to the investment community, IBN hosts the Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. During the episode, Energy and Water Development CEO Irma Velazquez talked with host Stuart Smith about her background and journey joining Energy and Water Development Corp. She also talked about the company’s core values and mission.…

Continue Reading

TuesdayMay 07, 2024 11:43 am

NetworkNewsBreaks – Lucid Group Inc. (NASDAQ: LCID) Releases Q1 2024 Financial Report

Lucid Group (NASDAQ: LCID), a company setting new standards for the luxury electric experience with the Lucid Air, America's most awarded new luxury vehicle, is reporting its first quarter 2024 financial results, for the period ended March 31, 2024. Highlights of the report show that the company produced 1,728 vehicles in first quarter, and is on track for annual production of approximately 9,000 vehicles; delivered 1,967 vehicles in Q1, up 39.9% compared to Q1 2023; reached Q1 revenue of $172.7 million; raised $1 billion via private placement to an affiliate of the Public Investment Fund (“PIF”); and has approximately $5.03 billion of total liquidity. “I…

Continue Reading

MondayMay 06, 2024 3:31 pm

NetworkNewsBreaks – Cemtrex Inc. (NASDAQ: CETX) Closes on Upsized Underwritten Public Offering Worth $10M

Cemtrex (NASDAQ: CETX), an advanced-security technology and industrial services company, has closed on a firm-commitment underwritten public offering. According to the announcement, the company will receive an estimated $10 million in gross proceeds from the offering, before standard deductions and expenses. Upsized from an original $9 million commitment, the base offering consisted of 11,764,705 common units or prefunded units; the purchase price of each common unit was $0.85, and the purchase price of each prefunded unit was $0.849. Cemtrex anticipates using the net proceeds from the offering for operations as well as to increase marketing efforts and invest in existing…

Continue Reading

MondayMay 06, 2024 3:20 pm

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today announced that it has received a staff determination letter on April 30, 2024, from the Listing Qualifications Department of the Nasdaq Stock Market LLC. In the letter, Nasdaq notified the company that, due to its non-compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the company's American Depositary Shares (“ADSs”) would be scheduled for delisting from the Nasdaq Capital Market and would be suspended…

Continue Reading

MondayMay 06, 2024 3:07 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance. According to the announcement, the research will be conducted in partnership with the National Research Council of Canada (“NRC”). “We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid…

Continue Reading